




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 1/00		A2	(11) International Publication Number: WO 98/59035
			(43) International Publication Date: 30 December 1998 (30.12.98)
(21) International Application Number: PCT/US98/12958 (22) International Filing Date: 22 June 1998 (22.06.98) (30) Priority Data: 60/050,691 25 June 1997 (25.06.97) US (71) Applicant (for all designated States except US): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health, Office of Technology Transfer [US/US]; Suite 325, 6011 Executive Boulevard, Rockville, MD 20852 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LUYTEN, Frank, P. [BE/BE]; Tervuvenlaan, B-3080 Tervuren (BE). ERLACHER, Ludwig [DE/US]; 4400 East West Highway, Bethesda, MD 20814 (US). (74) Agent: ALTMAN, Daniel, E.; Knobbe, Martens, Olson and Bear, 16th floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published Without international search report and to be republished upon receipt of that report.	

(54) Title: SERUM-FREE CELL GROWTH MEDIUM

(57) Abstract

A chemically defined-serum free growth medium for the *in vitro* and *ex vivo* of cells and cell lines. The medium consists of about a one to one ratio (v/v) of two basal growth media containing α -ketoglutarate, insulin, transferrin, selenium, bovine serum albumin, linoleic acid, ceruloplasmin, cholesterol, phosphatidyl-ethanolamine, α -tocopherol acid succinate, reduced glutathione, taurine, triiodothyronine, hydrocortisone, parathyroid hormone, L-ascorbic acid 2-sulfate, β -glycerophosphate, PDGF, EGF and FGF. Chondrocytes, when cultured in this medium in the presence of a cartilage derived morphogenetic protein or bone morphogenetic protein, retain their cartilaginous phenotype.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

SERUM-FREE CELL GROWTH MEDIUM

Field of the Invention

The present invention relates to a cell growth medium. More specifically, the invention relates to a chemically defined serum-free growth medium useful for the expansion of primary cells or cell lines in culture.

Background of the Invention

Culturing of mammalian cells is an essential technique for research into cellular processes, production of recombinant therapeutic proteins, and generation of expanded cells for transplantation purposes. Cell culture studies have led to the determination of numerous metabolic processes and the identification of growth factors, hormones and their receptors (*BioTechniques*, 5:534-542, 1987).

The composition of media used to culture cells is of paramount importance because of its influence on cell survival and cell response to various effectors. Conventional cell culture media comprise basal nutrient media supplemented with serum from various sources, most often fetal bovine serum, horse serum or human serum. However, the use of serum is undesirable for several reasons. Growth media containing serum may vary in composition, hormone content, and contaminants, thereby introducing extraneous factors and/or infectious agents into the culture system (*Bio Technology*, 11:49-53, 1993; *Pharm. Technol.*, 48:56, 1987). In addition, serum is expensive, impractical for large-scale production of therapeutics. Further, variance between serum lots and laboratory protocols is also a problem. Recent concerns by the FDA, the European community, and others about serum quality, contamination (i.e., bovine spongiform encephalopathy, bovine immunodeficiency virus), and increased demand have generated significant interest in the development and utility of serum-free growth media.

Significant advances have been made in the development of serum substitutes and serum-free media that address the inadequacies of media containing serum (*J. Tissue Cult. Meth.*, 14:45-50, 1992; *Biochem. Pharmacol.*, 38:3723-3729, 1989; *J. Tissue Cult. Meth.*, 12:13-16, 1989). Serum-free media provide many important advantages over serum-containing media, including lot-to-lot consistency, biological uniformity, and freedom from adventitious agents. Serum-free media are generally cost effective and low in protein content. All of these factors contribute to a more controlled examination of cellular, molecular and metabolic processes (*ATCC Connection*, 16(2):5-6, 1996).

Harrison et al. (*Exp. Cell Res.*, 192:340-345, 1991) describe a serum-free medium used for chondrocytes in suspension/agarose cultures. Addition of a cocktail of growth factors to this medium was sufficient to promote colony formation at levels comparable to medium containing 10% fetal bovine serum (FBS).

Serum-free technology is not entirely problem-free. Many serum-free media are highly specific to a particular cell type, are for short-term culturing only, or contain components extracted from serum. Very few available products can support primary cell cultures. Ideally, serum-free media should be compatible with various basal media and be useful for primary culturing and long-term maintenance of established cell lines. The present invention provides such a medium.

Summary of the Invention

One embodiment of the present invention is a cell growth medium consisting essentially of about a 1:1 ratio (v/v) of two basal cell culture media containing effective cell growth-promoting amounts of α -ketoglutarate,

ceruloplasmin, cholesterol, phosphatidylethanolamine, α -tocopherol acid succinate, reduced glutathione, taurine, triiodothyronine, hydrocortisone, parathyroid hormone, L-ascorbic acid 2-sulfate, β -glycerophosphate, platelet-derived growth factor (PDGF), epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF). Preferably, the medium contains about: 1×10^{-4} M α -ketoglutarate, 0.25 U/ml ceruloplasmin, 5 μ g/ml cholesterol, 2 μ g/ml phosphatidylethanolamine, 9×10^{-7} M α -tocopherol acid succinate, 10 μ g/ml reduced glutathione, 1.25 mg/ml taurine, 1.6×10^{-9} M triiodothyronine, 1×10^{-9} M hydrocortisone, 5×10^{-10} M parathyroid hormone, 50 μ g/ml L-ascorbic acid 2-sulfate, 10 mM β -glycerophosphate, 4 ng/ml PDGF, 10 ng/ml EGF and 10 ng/ml bFGF. Advantageously, the two basal cell culture media are selected from Dulbecco's modified Eagle's medium (DMEM), Ham's F-12, Essential modified Eagle's medium (EMEM) and RPMI-1640. The medium described above may further contain at least one cartilage derived morphogenetic protein. Preferably, the cartilage derived morphogenetic protein is CDMP-1 or CDMP-2. Advantageously, the medium further contains at least one bone morphogenetic protein. Preferably, the bone morphogenetic protein is OP-1.

The present invention also provides a method of growing or expanding cells or cell lines, comprising contacting the cells with a cell growth medium consisting essentially of about a 1:1 ratio (v/v) of two basal cell culture media containing effective cell growth-promoting amounts of α -ketoglutarate, ceruloplasmin, cholesterol, phosphatidylethanolamine, α -tocopherol acid succinate, reduced glutathione, taurine, triiodothyronine, hydrocortisone, parathyroid hormone, L-ascorbic acid 2-sulfate, β -glycerophosphate, platelet-derived growth factor, epidermal growth factor and basic fibroblast growth factor. Preferably, the cells are primary cells. In one aspect of this preferred embodiment, the cells are chondrocytes or marrow stromal fibroblasts. Advantageously, the cells are grown *in vitro*. Alternatively, the cells are grown *ex vivo*.

Another embodiment of the present invention is a method of maintaining a cartilaginous phenotype in chondrocytes *in vitro*, comprising culturing the chondrocytes in serum-free medium comprising a cartilage-derived morphogenetic protein and/or bone morphogenetic protein.

The present invention also provides a method of repairing a joint surface defect in a mammal in need thereof, comprising the steps of:

- isolating normal cartilage in the vicinity of the surface defect;
- isolating chondrocytes from the cartilage;
- culturing the chondrocytes in serum-free medium comprising a cartilage-derived morphogenetic and/or bone morphogenetic protein whereby the chondrocytes are expanded; and
- implanting the expanded chondrocytes into the surface defect.

Preferably, the serum-free medium is the medium described above. Advantageously, the step of isolating chondrocytes comprises digestion of cartilage with collagenase.

Brief Description of the Figure

Figure 1 is a graph showing human fetal chondrocyte expansion as monolayer cultures in the serum-free medium of the invention (basal medium + EGF + PDGF + FGF), the serum-free medium + cartilage-derived morphogenetic protein 1 (CDMP-1), or basal medium containing 10% fetal bovine serum.

Detailed Description of the Preferred Embodiments

The present invention provides a chemically defined serum-free medium which can be used to maintain and expand cells, primary cells and cell lines both *in vitro* and *ex vivo*. The medium can be used for any desired cell type, and can be used for both short-term and long-term culturing of cells. The medium consists of two basal cell culture media (about 1:1, v/v) (Collaborative Biomedical Products, Bedford, MA; GIBCO/BRL, Gaithersburg, MD) containing effective cell growth-promoting amounts of insulin, transferrin, selenium, bovine serum albumin, linoleic acid, α -ketoglutarate, ceruloplasmin, cholesterol, phosphatidylethanolamine, α -tocopherol acid succinate, reduced glutathione, taurine, triiodothyronine, hydrocortisone, parathyroid hormone, L-ascorbic acid 2-sulfate and β -glycerophosphate. The medium also contains platelet-derived growth factor (PDGF)-AB or BB, epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF). All supplements are available from Sigma Chemical Co., St. Louis, MO. Growth factors are available from, for example, Collaborative Medical Products.

Although Ham's F-12/Dulbecco's modified Eagle's medium (DMEM) (about 1:1) are the two preferred basal media, the use of other basal media combinations is also contemplated, including Essential modified Eagle's medium (EMEM) and RPMI-1640. In a preferred embodiment, the concentrations of the compounds listed above are about:

Table 1

15

20

25

30

35

Compound	Concentration
α -ketoglutarate	1×10^{-4} M
insulin	6.25 μ g/ml
transferrin	6.25 μ g/ml
selenium	6.25 ng/ml
bovine serum albumin	1.25 mg/ml
linoleic acid	5.35 μ g/ml
ceruloplasmin	0.25 U/ml
cholesterol	5 μ g/ml
phosphatidylethanolamine	2 μ g/ml
α -tocopherol acid succinate	9×10^{-7} M
reduced glutathione	10 μ g/ml
taurine	1.25 μ g/ml
triiodothyronine	1.6×10^{-9} M
hydrocortisone	1×10^{-9} M
parathyroid hormone	5×10^{-10} M
L-ascorbic acid 2-sulfate	50 μ g/ml
β -glycerophosphate	10 mM
PDGF-AB or -BB	4 ng/ml

-4-

EGF	10 ng/ml
bFGF	10 ng/ml

Although the preferred concentration of each component is as listed in Table 1, these concentrations can be adjusted to suit any desired cell or cell line. This serum-free medium comprises basal medium (BM) plus various components and growth factors. The medium is suitable for anchorage-dependent growth of cells for laboratory experimentation, for large-scale production of recombinant proteins and for expansion of cells for transplantation or implantation. For example, fetal or adult pancreatic islet cells can be expanded *in vitro* in the serum-free medium of the invention using standard cell culture techniques, then implanted into a diabetic patient. The medium can also be used to effectively culture marrow stromal fibroblasts which differentiate into bone cells.

The medium can also be used to expand chondrocytes as discussed in Example 1. This will allow *in vivo* cartilage repair. In this embodiment, cartilage is removed from a non-damaged cartilage area around a damage site and digested with collagenase. The resulting chondrocytes are expanded *ex vivo* in the serum-free medium of the invention, then injected or implanted into the cartilage defect site. Similarly, marrow stromal fibroblasts can be isolated from a normal area adjacent a bone defect, expanded *ex vivo* in serum-free medium and administered at the site of a bone defect.

The expansion of chondrocytes (articular or fetal limb) in the serum-free medium of the invention containing PDGF, EGF and FGF results in the loss of two main cartilage-specific phenotypic markers, type II collagen and proteoglycan aggrecan, which contribute to the maintenance of the cartilaginous phenotype. These molecules are critical to extracellular matrix synthesis. Chondrocytes cultured in this serum free medium are fibroblastic in appearance and longitudinal in shape, compared to their typical round morphology. The presence of these two phenotypic markers is important, because the Food and Drug Administration (FDA)/Center for Biologics Evaluation and Research (CBER) requires that protocols relating to *ex vivo* expansion of articular chondrocytes for repair of joint surfaces prove that the expanded cell populations are very similar to the native chondrocytes. This can be assessed by evaluating the expression of proteoglycan aggrecan and type II collagen at the end of the expansion protocol by Northern blotting, immunoblotting or fluorescence-activated cell sorting (FACS).

In vitro studies were performed to investigate the role of Bone Morphogenetic Proteins/Cartilage-Derived Morphogenetic Proteins (BMPs/CDMPs) in maintaining the cartilaginous phenotype of human articular and fetal limb chondrocytes under serum-free conditions using Ham's F-12/DMEM (1:1) containing the compounds listed in Table 1. One such BMP is osteogenic protein-1 (OP-1; also called BMP-7) (Creative Biomolecules). The inclusion of CDMP-1 and/or OP-1, both at 50 ng/ml in the serum-free medium contributed to the maintenance and re-expression of proteoglycan aggrecan and type II collagen in cultured human fetal chondrocytes as determined by northern blotting of mRNA using labeled cDNA probes to type II collagen and proteoglycan aggrecan. It is contemplated that the inclusion of one or more CDMPs (CDMP-1, CDMP-2) and/or one or more BMPs (i.e. OP-1, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6) in any serum-free medium capable of supporting cell growth will contribute to the maintenance of the cartilaginous phenotype and the proteoglycan aggrecan and type II collagen markers.

In addition, other cell types and cell lines in monolayer cultures survived in the serum-free medium containing growth factor cocktail (PDGF, EGF, FGF) with or without CDMPs (i.e., mouse ATDC5 embryonic teratinocarcinoma cells; mouse calvarial osteoblastic clonal cell line MC3T3-E1; the mouse myoblast cell line C2C12; R mutant Mv1Lu cells; and the rat osteoprogenitor-like cell line ROB-C26), and some continued to proliferate.

5 The efficacy of cell expansion was compared using Ham's F-12/DMEM (1:1) containing the compounds shown in Table 1 with 10% fetal bovine serum versus the same medium with growth factors (PDGF, FGF and EGF) replacing the serum. Surprisingly, every primary cell or cell line tested with the serum-free medium expanded in culture almost as quickly or equally fast than in the serum-containing medium. This medium will contribute to the reproducibility of cell expansion protocols, provides lot-to-lot consistency, biological uniformity and freedom from
10 adventitious agents. The medium also performs well regardless of the cell type used.

Various CDMP assays performed in cultured cells, including DNA determination, alkaline phosphatase activity and proteoglycan biosynthesis could only be performed in the serum-free medium of the invention; the presence of serum significantly interfered with these assays. Thus, the serum-free medium is essential to the success of these
15 assays.

The growth of human fetal chondrocytes in the serum-free medium of the invention is discussed in the following example.

Example 1

Growth of human fetal chondrocytes in serum-free medium

Human fetal limbs from 52 to 79 day old fetuses were provided by the Laboratory for Human Embryology,
20 Department of Pediatrics, University of Washington, Seattle, WA. This was approved by the Office of Human Subjects Research, National Institutes of Health. The cartilaginous cores were carefully dissected from the surrounding fetal tissue and the chondrocytes were released by a six hour digestion in 0.2% collagenase B (Boehringer Mannheim, Indianapolis, IN) in basal medium lacking growth factors (Table 1) at 37°C. Chondrocytes were cultured in either basal medium containing EGF, PDGF and FGF (Table 1); basal medium containing EGF, PDGF,
25 FGF and 50 ng/ml CDMP-1; or basal medium plus 10% fetal bovine serum for two to six days. Cell expansion at days 2, 3, 4, 5 and 6 was assessed by determination of cellular DNA content using bisbenzimidazole (Hoechst 33258, Sigma, St. Louis, MO) (Labarca et al., *Anal. Biochem.*, 102:344-352, 1980). As shown in Fig. 1, by day 6 in culture, human chondrocytes exhibited the same degree of expansion in either serum-free or serum-containing medium.

Example 2

Expression and purification of CDMPs

30 The cDNAs encoding CDMP-1 and CDMP-2 were isolated by Chang et al. (*J. Biol. Chem.*, 269:28227-28234, 1994) and are also described in International Publication W096/14335. A cDNA encoding the mature *cdmp-1* was modified for insertion into an *E. coli* expression vector by site directed mutagenesis using the method of Kunkel (*Proc. Natl. Acad. Sci. U.S.A.*, 82:488-492, 1985). Following the pro-domain and in close proximity to the RXXR processing site, a leucine residue was converted to a methionine translational initiation codon with a corresponding
35 *NcoI* restriction site, while a 3' *XhoI* site was similarly introduced immediately after the translational stop codon.

The *NcoI* to *XhoI* fragment containing the open reading frame for mature *cdmp-1* was ligated to a tetracycline resistant pBR322-derived expression vector. Fermentation was done in shaker flasks using 2YT medium with addition of indolacrylic acid at the appropriate time for induction of the tryptophan promoter (Nichols et al., *J. Mol. Biol.*, 146:45-54, 1981). Large exclusion bodies containing CDMP-1 accumulated. A cDNA for *cdmp-2* was similarly
5 tailored for expression. Since the CDMP-2 expression level was quite low, part of the N-terminal region of the highly expressed *cdmp-1* was spliced with the 7-cysteine domain of *cdmp-2* at the first cysteine, where both genes share a *PstI* site. Induced cell cultures (250 ml) were centrifuged (11,000 x g, 10 min., 4°C), followed by resuspension of the cell pellets in 50 ml of 25 mM Tris-HCl, 10 mM EDTA, pH 8.0 (1 X TE) containing 100 µg/ml lysozyme. The cell suspensions were incubated overnight at 37°C, chilled on ice and sonicated. Inclusion bodies were isolated by
10 centrifugation (11,000 x g, 20 min., 4°C) and resuspended in 1 X TE. The final washed inclusion body pellets were resuspended in 40 ml 1 X TE, 15% glycerol and stored at -20°C.

Reduced and denatured inclusion body protein solutions were prepared by dissolving aliquots of pelleted inclusion bodies in 100 mM Tris-HCl, 10 mM EDTA, 6 M guanidine HCl, 10 mM dithiothreitol (DTT), pH 8.0 (final protein concentration of 4-6 mg/ml). The inclusion body protein solutions were incubated at 37°C for 30 min., then
15 diluted 40-fold with refolding buffer (100 mM Tris, 10 mM EDTA, 1 M NaCl, 2% 3-[3-cholamidopropyl] dimethylammonio]-2-hydroxy-1-propanesulfonic acid (CHAPS), 5 mM reduced glutathione, 2.5 mM oxidized glutathione, pH 8.7). The refolding reactions were incubated for 72 hours at 4°C. The folding reactions were dialyzed extensively against 10 mM HCl, then clarified by centrifugation (11,000 x g, 20 min., 4°C). The solutions were concentrated using a stirred cell concentrator and YM10 MWCO membranes (Amicon). The concentrated proteins
20 were then lyophilized. The lyophilized proteins were resuspended in 0.8 ml 0.1% trifluoroacetic acid (final acetonitrile concentration - 30%). The protein solutions were fractionated by semi-preparative C4 Reverse Phase High Performance Liquid Chromatography (HPLC) using a linear acetonitrile gradient (30-70% in 0.1% TFA). Aliquots of each fraction were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 15% gels under non-reducing conditions after reduction and alkylation. Peak dimer fractions were pooled and concentrations
25 were estimated by UV absorbance spectra obtained at 280 nm. Protein pools were stored at -20°C.

Example 3

Repair of cartilage defects

An individual with a joint surface (i.e. knee) defect is identified and healthy cartilage surrounding the defect is surgically removed. The cartilage is then digested with collagenase using standard methods to isolate individual
30 chondrocytes. Chondrocytes are cultured in basal medium containing the components listed in Table 1 and containing CDMP-1 and/or CDMP-2. The expanded chondrocytes are tested for the presence of proteoglycan aggrecan and type II collagen markers, then surgically implanted into the joint defect site. Significant improvement in both clinical signs and symptoms as well as repair of the defect of the joint surface occurs in response to this procedure.

It should be noted that the present invention is not limited to only those embodiments described in the
35 Detailed Description. Any embodiment which retains the spirit of the present invention should be considered to be within its scope. However, the invention is only limited by the scope of the following claims.

WHAT IS CLAIMED IS:

1. A cell growth medium consisting essentially of about a 1:1 ratio (v/v) of two basal cell culture media, said medium containing effective cell growth-promoting concentrations of α -ketoglutarate, ceruloplasmin, cholesterol, phosphatidyl-ethanolamine, α -tocopherol acid succinate, reduced glutathione, taurine, triiodothyronine, hydrocortisone, parathyroid hormone, L-ascorbic acid 2-sulfate, β -glycerophosphate, platelet-derived growth factor (PDGF), epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF).
2. The medium of Claim 1, wherein said basal cell culture media are selected from the group consisting of Ham's F-12, Dulbecco's modified Eagle's medium (DMEM), Essential modified Eagle's medium (EMEM) and RPMI-1640.
3. The medium of Claim 1, wherein the concentration of α -ketoglutarate is about 1×10^{-4} M.
4. The medium of Claim 1, wherein the concentration of ceruloplasmin is about 0.25 U/ml.
5. The medium of Claim 1, wherein the concentration of cholesterol is about 5 μ g/ml.
6. The medium of Claim 1, wherein the concentration of phosphatidyl-ethanolamine is about 2 μ g/ml.
7. The medium of Claim 1, wherein the concentration of α -tocopherol acid succinate is about 9×10^{-7} M.
8. The medium of Claim 1, wherein the concentration of reduced glutathione is about 10 μ g/ml.
9. The medium of Claim 1, wherein the concentration of taurine is about 1.25 μ g/ml.
10. The medium of Claim 1, wherein the concentration of triiodothyronine is about 1.6×10^{-9} M.
11. The medium of Claim 1, wherein the concentration of hydrocortisone is about 1×10^{-9} M.
12. The medium of Claim 1, wherein the concentration of parathyroid hormone is about 5×10^{-10} M.
13. The medium of Claim 1, wherein the concentration of L-ascorbic acid 2-sulfate is about 50 μ g/ml.
14. The medium of Claim 1, wherein the concentration of PDGF is about 4 ng/ml.
15. The medium of Claim 1, wherein the concentration of EGF is about 10 ng/ml.
16. The medium of Claim 1, wherein the concentration of bFGF is about 10 ng/ml.
17. The medium of Claim 1, wherein said medium further contains at least one cartilage derived morphogenetic protein.
18. The medium of Claim 17, wherein said cartilage derived morphogenetic protein is CDMP-1 or CDMP-2.
19. The medium of Claim 1, wherein said medium further contains at least one bone morphogenetic protein.
20. The medium of Claim 19, wherein said bone morphogenetic protein is OP-1.
21. A method of growing or expanding cells or cell lines, comprising contacting said cells with a cell growth medium consisting essentially of about a 1:1 ratio (v/v) of two basal cell culture media containing effective cell growth-promoting amounts of α -ketoglutarate, ceruloplasmin, cholesterol, phosphatidylethanolamine, α -tocopherol acid succinate, reduced glutathione, taurine, triiodothyronine, hydrocortisone, parathyroid hormone, L-ascorbic acid 2-sulfate, β -glycerophosphate, PDGF, EGF and bFGF.

22. The method of Claim 21, wherein said cells are primary cells.
23. The method of Claim 21, wherein said cells are chondrocytes or marrow stromal fibroblasts.
24. The method of Claim 21, wherein said cells are grown *in vitro*.
25. The method of Claim 21, wherein said cells are grown *ex vivo*.
- 5 26. A method of maintaining a cartilaginous phenotype in chondrocytes *in vitro*, comprising culturing said chondrocytes in serum-free medium comprising a cartilage-derived morphogenetic protein and/or bone morphogenetic protein.
27. A method of repairing a joint surface defect in a mammal in need thereof, comprising the steps of:
- 10 isolating normal cartilage in the vicinity of said surface defect;
isolating chondrocytes from said cartilage;
culturing said chondrocytes in serum-free medium comprising a cartilage-derived morphogenetic and/or bone morphogenetic protein whereby said chondrocytes are expanded; and
implanting said expanded chondrocytes into said surface defect.
- 15 28. The method of Claim 27, wherein said serum-free medium is the medium of Claim 1.
29. The method of Claim 27, wherein said isolating chondrocytes step comprises digestion of said cartilage with collagenase.

1/1




FIG. 1




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 5/00, 5/08		A3	(11) International Publication Number: WO 98/59035
			(43) International Publication Date: 30 December 1998 (30.12.98)
(21) International Application Number: PCT/US98/12958		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 22 June 1998 (22.06.98)			
(30) Priority Data: 60/050,691 25 June 1997 (25.06.97) US			
(71) Applicant (for all designated States except US): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health, Office of Technology Transfer [US/US]; Suite 325, 6011 Executive Boulevard, Rockville, MD 20852 (US).		Published With international search report.	
(72) Inventors; and (75) Inventors/Applicants (for US only): LUYTEN, Frank, P. [BE/BE]; Tervurenlaan, B-3080 Tervuren (BE). ER-LACHER, Ludwig [DE/US]; 4400 East West Highway, Bethesda, MD 20814 (US).		(88) Date of publication of the international search report: 18 March 1999 (18.03.99)	
(74) Agent: ALTMAN, Daniel, E.; Knobbe, Martens, Olson and Bear, 16th floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).			

(54) Title: SERUM-FREE CELL GROWTH MEDIUM

(57) Abstract

A chemically defined-serum free growth medium for the *in vitro* and *ex vivo* of cells and cell lines. The medium consists of about a one to one ratio (v/v) of two basal growth media containing α -ketoglutarate, insulin, transferrin, selenium, bovine serum albumin, linoleic acid, ceruloplasmin, cholesterol, phosphatidyl-ethanolamine, α -tocopherol acid succinate, reduced glutathione, taurine, triiodothyronine, hydrocortisone, parathyroid hormone, L-ascorbic acid 2-sulfate, β -glycerophosphate, PDGF, EGF and FGF. Chondrocytes, when cultured in this medium in the presence of a cartilage derived morphogenetic protein or bone morphogenetic protein, retain their cartilaginous phenotype.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakistan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/12958

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C12N5/00 C12N5/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HARRISON ET AL: "OSTEOGENIN PROMOTES REEXPRESSION OF CARTILAGE PHENOTYPE BY DEDIFFERENTIATED ARTICULAR CHONDROCYTES IN SERUM-FREE MEDIUM" EXPERIMENTAL CELL RESEARCH, vol. 192, 1991, pages 340-345, XP002079037 cited in the application see the whole document ---	1-16, 19, 21-29
X	CHEN P ET AL: "OSTEOGENIC PROTEIN-1 PROMOTES GROWTH AND MATURATION OF CHICK STERNAL CHONDROCYTES IN SERUM-FREE CULTURES" JOURNAL OF CELL SCIENCE, vol. 108, no. 1, 1995, pages 105-114, XP000609871 see the whole document --- -/--	26, 27, 29



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 December 1998

Date of mailing of the international search report

12 01 1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Sitch, W

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/12958

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>LUYTEN F P ET AL: "Recombinant bone morphogenetic protein -4, transforming growth factor-beta 1, and activin A enhance the cartilage phenotype of articular chondrocytes in vitro." EXPERIMENTAL CELL RESEARCH, (1994 FEB) 210 (2) 224-9. JOURNAL CODE: EPB. ISSN: 0014-4827., XP002088388 United States see page 224 see abstract</p>	26,27,29
A	<p>"SIGMA CELL CULTURE, 1994 CATALOGUE AND PRICE LIST" 1994, SIGMA XP002079038 see page 219 - page 220</p>	1-25
A	<p>WO 91 10726 A (US GOVERNMENT) 25 July 1991 see page 15 - page 16; table 2</p>	1-25
A	<p>WO 95 00632 A (AMGEN INC) 5 January 1995 see page 7, line 33 - page 10, line 10</p>	1-25
A	<p>CHANG S C ET AL: "CARTILAGE-DERIVED MORPHOGENETIC PROTEINS" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 45, 11 November 1994, pages 28227-28234, XP002058787 cited in the application see page 28227 see abstract</p>	26,27,29
P.X	<p>ERLACHER L ET AL: "Presence of cartilage - derived morphogenetic proteins in articular cartilage and enhancement of matrix replacement in vitro." ARTHRITIS AND RHEUMATISM, (1998 FEB) 41 (2) 263-73. JOURNAL CODE: 90M. ISSN: 0004-3591., XP002088389 United States see page 263 see abstract</p>	26,27,29
E	<p>WO 98 44874 A (BARNES JEWISH HOSPITAL) 15 October 1998 see page 6, line 2 - page 7, line 13 see page 23, line 18 - page 26, line 2 see page 26 - page 29; example 1</p>	26,27,29

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 98/12958

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 27-29 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-25

A cell growth medium comprising two basal cell culture media, and also comprising at least platelet-derived growth factor, epidermal growth factor and basic fibroblast growth factor; a method of growing or expanding cells or cell lines comprising contacting said cells with a cell growth medium, wherein such medium comprises two basal cell culture media, and also comprising at least platelet-derived growth factor, epidermal growth factor and basic fibroblast growth factor.

2. Claims: 26-29

A method of maintaining a cartilaginous phenotype in chondrocytes in vitro comprising culturing such in serum-free medium comprising a cartilage-derived morphogenetic protein and/or bone morphogenetic protein; a method of repairing a joint surface defect in a mammal comprising use of chondrocytes, wherein such chondrocytes have been cultured in serum-free medium comprising a cartilage-derived morphogenetic protein and/or bone morphogenetic protein.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte Jonal Application No

PCT/US 98/12958

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9110726 A	25-07-1991	AT 145235 T	15-11-1996
		AU 653927 B	20-10-1994
		AU 7300191 A	05-08-1991
		DE 69123140 D	19-12-1996
		DE 69123140 T	03-04-1997
		DK 512066 T	02-12-1996
		EP 0512066 A	11-11-1992
		JP 7089954 B	04-10-1995
		JP 5502379 T	28-04-1993
WO 9500632 A	05-01-1995	US 5405772 A	11-04-1995
		AU 678836 B	12-06-1997
		AU 7112494 A	17-01-1995
		CA 2165335 A	05-01-1995
		EP 0703978 A	03-04-1996
		JP 8508891 T	24-09-1996
WO 9844874 A	15-10-1998	NONE	

10

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**

THIS PAGE BLANK (USPTO)